NASDAQ:ASMB - Assembly Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$36.46 -0.90 (-2.41 %)
(As of 09/26/2018 04:20 AM ET)
Previous Close$37.36
Today's Range$36.38 - $38.42
52-Week Range$27.00 - $67.36
Volume118,400 shs
Average Volume206,649 shs
Market Capitalization$918.62 million
P/E Ratio-15.72
Dividend YieldN/A
Beta0.83
Assembly Biosciences logoAssembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ASMB
CUSIP92282210
Phone317-210-9311

Debt

Debt-to-Equity RatioN/A
Current Ratio7.43
Quick Ratio7.43

Price-To-Earnings

Trailing P/E Ratio-15.72
Forward P/E Ratio-8.85
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.02 million
Price / Sales102.87
Cash FlowN/A
Price / CashN/A
Book Value$5.62 per share
Price / Book6.49

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-42,800,000.00
Net Margins-457.20%
Return on Equity-66.34%
Return on Assets-40.23%

Miscellaneous

Employees79
Outstanding Shares25,450,000
Market Cap$918.62 million

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences Inc (NASDAQ:ASMB) posted its earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($1.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.88) by $0.43. The biopharmaceutical company earned $3.22 million during the quarter, compared to the consensus estimate of $3.30 million. Assembly Biosciences had a negative return on equity of 66.34% and a negative net margin of 457.20%. View Assembly Biosciences' Earnings History.

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Assembly Biosciences.

What price target have analysts set for ASMB?

4 equities research analysts have issued 12-month price objectives for Assembly Biosciences' stock. Their predictions range from $45.00 to $75.00. On average, they anticipate Assembly Biosciences' share price to reach $61.00 in the next twelve months. This suggests a possible upside of 67.3% from the stock's current price. View Analyst Price Targets for Assembly Biosciences.

What is the consensus analysts' recommendation for Assembly Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences.

Who are some of Assembly Biosciences' key competitors?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the folowing people:
  • Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 46)
  • Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 68)
  • Mr. Thomas E. Rollins, Exec. Officer (Age 62)
  • Mr. David J. Barrett CPA, Strategic Advisor (Age 42)

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Jennison Associates LLC (12.03%), BlackRock Inc. (6.04%), Janus Henderson Group PLC (3.92%), Northern Trust Corp (0.95%), Emerald Advisers Inc. PA (1.14%) and Emerald Mutual Fund Advisers Trust (0.99%). Company insiders that own Assembly Biosciences stock include Derek A Small, Uri A Lopatin and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences.

Which major investors are selling Assembly Biosciences stock?

ASMB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Baker BROS. Advisors LP, BlueMountain Capital Management LLC, California Public Employees Retirement System, Victory Capital Management Inc., Millennium Management LLC and WINTON GROUP Ltd. Company insiders that have sold Assembly Biosciences company stock in the last year include Uri A Lopatin and William R Ringo. View Insider Buying and Selling for Assembly Biosciences.

Which major investors are buying Assembly Biosciences stock?

ASMB stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, FMR LLC, Prosight Management LP, Jennison Associates LLC and Alps Advisors Inc.. View Insider Buying and Selling for Assembly Biosciences.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $36.46.

How big of a company is Assembly Biosciences?

Assembly Biosciences has a market capitalization of $918.62 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 79 workers across the globe.

What is Assembly Biosciences' official website?

The official website for Assembly Biosciences is http://www.assemblybio.com.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]


MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  288
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel